Stockscreener 앱 받기
1.16
31.76%
-0.54
시간 외 거래:
1.19
0.03
+2.59%
Clearmind Medicine Inc 주식(CMND)의 최신 뉴스
Why Did CMND Stock Jump 40% Today? - Stocktwits
Clearmind Medicine to Acquire Majority Stake in Charging Robotics for $2.5 Million - marketscreener.com
CMND Stock Slides As Clearmind Medicine Tightens Cash Belt - StocksToTrade
Clearmind to acquire 51% stake in EV charging firm for $2.5M By Investing.com - Investing.com South Africa
Clearmind Tumbles on Buying into Charging Robotics - Baystreet.ca
Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million - Yahoo Finance
Clearmind Medicine Stock Slides Friday: What's Happening? - Benzinga
CMND Stock Pulls Back As Traders Eye Cash Runway - StocksToTrade
CMND Stock Pops As Clearmind Advances AUD Drug To Phase IIa - timothysykes.com
Clearmind to acquire 51% stake in EV charging firm for $2.5M - Investing.com UK
Clearmind Medicine Inc. (CMND) moves into EV wireless charging with a controlling deal - Stock Titan
A biotech plans to buy most of a wireless charging company for robotaxis - Stock Titan
Debt-for-share swap at $1 sets new floor at Clearmind (CMND) - Stock Titan
Clearmind Medicine Inc. (CMND) Stock: Jumps Nearly 10% as Phase IIa AUD Trial Begins - Blockonomi
Clearmind starts Phase IIa AUD trial of CMND-100 - Stock Titan
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled - manilatimes.net
Clearmind Medicine Announces Initiation of Phase IIa Trial for CMND-100 in Alcohol Use Disorder - Quiver Quantitative
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - manilatimes.net
NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - NewMediaWire
SciSparc: NeuroThera-Clearmind Collaboration Advances - GlobeNewswire
FDA Guidance Includes MDMA as a Psychedelic Drug; SciSparc Patent Application Published - Stock Titan
Clearmind (CMND) Market: Adds 0.87% to Close at $1.74; Chart Watch: Support at $1.65 and Resistance at $1.83 Frame the Range in the Latest SessionVolume Rate Change - vinanet.vn
Clearmind Medicine Company Profile & Introduction - Moomoo
Clearmind Medicine (CMND) Holds Near $1.86 as Biotech Stock Consolidates Within Key RangeFibonacci Extension - vinanet.vn
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial - Benzinga
Clearmind Medicine Receives DSMB Approval to Advance CMND-100 Clinical Trial in Patients With Alcohol Use Disorder - Quiver Quantitative
Clearmind's CMND-100 Will Be Tested in People With Alcohol Use Disorder - Stock Titan
Clearmind Medicine Inc. (NASDAQ:CMND) - intelligentinvestor.com.au
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint - manilatimes.net
Clearmind Medicine (CMND) holders report 9.99% cap on warrant-based stake - Stock Titan
Clearmind Medicine (CMND) reports intranasal MEAI permeation near 98% in study - Stock Titan
Clearmind Medicine Announces Positive Permeation Results For Intranasal Meai Formulation - TradingView
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery - manilatimes.net
Clearmind Medicine Reports Positive Permeation Results for Intranasal MEAI Program - Quiver Quantitative
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, ... - Enidnews.com
Clearmind’s nasal MEAI stays longer on tissue with comparable drug transport - Stock Titan
Clearmind Medicine (CMND) Drops 6.86% to $1.63, Testing Critical Support at $1.55Symmetrical Triangle - vinanet.vn
Clearmind Medicine (CMND) Holds Steady at $1.75 as Traders Eye Resistance Near $1.84Wave Equality - vinanet.vn
Clearmind Medicine (Nasdaq: CMND) wins DSMB nod to advance AUD trial - Stock Titan
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study - The Manila Times
CMND-100 Set to Enter Human Testing for Moderate-to-Severe Alcohol Use Disorder - Stock Titan
Clearmind advances CMND-100 alcohol use disorder trial into patient testing after Phase I safety readout - Bitget
Clearmind Medicine (CMND) Edges Higher: Biotech Stock Holds Steady Near $1.74 as Support FirmsOvervalued Signals - vinanet.vn
Clearmind Medicine (CMND) Shares Advance Nearly 5% as Biotech Momentum BuildsStop Hunt - dars.gov.et
Clearmind Medicine to acquire 51% stake in EV charging firm By Investing.com - Investing.com Nigeria
Clearmind Medicine Signs Letter Of Intent To Acquire 51% Majority Stake In Ev Wireless Charging Solutions For Automated Parking Systems Company - TradingView
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company - The Manila Times
Clearmind Medicine (Nasdaq: CMND) signs LOI for 51% EV charging stake - Stock Titan
Clearmind Medicine (Nasdaq: CMND) posts encouraging CMND-100 Phase I/II safety data - Stock Titan
Clearmind completes Part A of FDA-regulated tri... - Pluang
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial - The Manila Times
Clearmind Medicine Completes Treatment of All Participants in Part A of Phase I/II AUD Trial for CMND-100 - Quiver Quantitative
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial - GlobeNewswire Inc.
Clearmind Medicine Inc (CMND) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Clearmind Medicine Inc. Revenue Breakdown – FWB:CWY0 - TradingView
Clearmind Medicine Inc (CMND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Clearmind Medicine Inc (CMND) Valuation: PE, PB & Fair Value Analysis - TradingKey
Clearmind Medicine Inc (CMND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clearmind Medicine Inc (CMND) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CMND|Clearmind Medicine Inc|Price:1.628|Chg%:+0.018 - TradingKey
CMND|Clearmind Medicine Inc|Price:1.615|Chg%:-0.045 - TradingKey
0.86%
0.31%
자본화:
|
볼륨(24시간):